Baxter Reports 4Q and 2018 Outlook In Line With Our Expectations
We don’t expect a major change to our fair value estimate for narrow-moat Baxter as the company’s fourth-quarter results mostly matched our expectations. Excluding currency, cyclophosphamide, and exited product categories, quarterly revenue climbed 2%. This includes the previously estimated $70 million top-line and $0.06 EPS hit from hurricane-related manufacturing issues in Puerto Rico, which primarily drove the 30-basis-point decline in adjusted operating margin from last year. Baxter continue...Baxter International, through its subsidiaries, provides a portfolio of healthcare products, including acute and chronic dialysis therapies; sterile intravenous solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision. The company manages its business based on three geographic segments: Americas (North and South America), Europe, Middle East and Africa and Asia-Pacific.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.